Skip to Main Content

Douglas Melton, one of the leading stem cell researchers in the world, is leaving Harvard University to join Vertex Pharmaceuticals, where he says he will pursue his deeply personal, decades-long quest to create therapies for type 1 diabetes.

Both his adult children have the disease, which affects the regulation of blood sugar and afflicts 1.9 million Americans.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment